Concepedia

Patrick Angibaud

PA

Statistics

Publications

28

Citations

1.5K

H-Index

21

Active since

1991

Affiliations

Centre National de la Recherche Scientifique(Current)

Janssen (Belgium)

Janssen (France)

ESPCI Paris

ParisTech

Patrick Angibaud is an author at Centre National de la Recherche Scientifique specializing in chemistry, organic chemistry, and heterocyclic chemistry.

Publications per year

1991–2019

28

Publications

28

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec et al. · Molecular Cancer Therapeutics · 2017 · 340 citations · Full text

, , +17

JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity

Janine Arts, Peter King, Ann Marin et al. · Clinical Cancer Research · 2009 · 232 citations

, , +12

Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA<sup>TM</sup>

Patrick Angibaud, Marc Venet, Walter Filliers et al. · European Journal of Organic Chemistry · 2004 · 119 citations

, , +14

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

Janine Arts, Patrick Angibaud, Ann Mariën et al. · British Journal of Cancer · 2007 · 89 citations · Full text

, , +15

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Christopher W. Murray, David R. Newell, Patrick Angibaud · MedChemComm · 2019 · 79 citations

, , +8

1–5 of 28